Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Lokavant provides clinical trial intelligence
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Subscribe To Our Newsletter & Stay Updated
